Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction

Expert Opinion on Investigational Drugs

Volumn 11, Issue 11, 2002, Pages 1605-1613

  Kuan, James ^a   Brock, Gerald ^a  

^a ST JOSEPH S HEALTH CENTRE   (Canada)

Author keywords

Cialis ; Erectile dysfunction; IC351; Phosphodiesterase inhibitor; Tadalafil

Indexed keywords

2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; AGENTS ACTING ON THE GENITAL SYSTEM; APOMORPHINE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE; PLACEBO; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

ARTICLE; BACKACHE; DOSE RESPONSE; DRUG ALCOHOL INTERACTION; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPEPSIA; ENZYME INHIBITION; ERECTILE DYSFUNCTION; FLUSHING; FOOD DRUG INTERACTION; HEADACHE; HUMAN; MALE; MYALGIA; RHINITIS; TREATMENT FAILURE; VISUAL DISORDER;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CARBOLINES; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 0036849101     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.11.11.1605     Document Type: Article

References (15)

1. FELDMAN HA, GOLDSTEIN I, HATZICHRISTOU DG, KRANE RJ, MCKINLAY JB: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J. Urol. (1994) 151(1):54-61.
2. SAENZ DE TEJADA I: Nitric oxide as a mediator of relaxation of the corpus cavernosum. N. Engl. J. Med. (1992) 326(24):1638.
3. LINCOLN TM, CORNWELL TL: Towards an understanding of the mechanism of action of cyclic AMP and cyclic GMP in smooth muscle relaxation. Blood Vessels (1991) 28(1-3): 129-137.
4. THOMPSON WJ: Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol. Ther. (1991) 51(1):13-33.
5. BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active Type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
6. LEE IC, SURRIDGE D, MORALES A et al.: The prevalence and influence of significant psychiatric abnormalities in men undergoing comprehensive management of organic ED. Int. J. Impot. Res. (2000) 12:47-51.
7. ARAUJO AB, JOHANNES CB, FELDMAN HA et al.: Relation between psychosocial risk factors and incident ED: Prospective results from the Massachusetts Male Aging Study. Am. J. Epidemiol. (2000) 152:533-541.
8. KRANE TJ, GOLDSTEIN I, SAENZ DE TEJADA I: Impotence. N. Engl. J. Med. (1989) 321:1648.
9. McKINLAY JB: The world-wide prevalence and epidemiology of ED. Int. J. Impot. Res. (2000) 12(Suppl. 4):S6-S11.
10. WHO INTERNATIONAL SOCIETY FOR IMPOTENCE RESEARCH: Oral non-endocrine treatment. Erectile Dysfunction, Health Publication Ltd (2000).
11. PORST H: The rationale for prostaglandin E1 in erectile failure a survey of worldwide experience. J. Urol. (1996) 155:802-815.
12. ZIPPE CD, KEDIA AW, KEDIA K, NELSON DR, AGARWAL A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate. Urology (1998) 52:963-966.
13. LOWENTRITT BH, SCARDINO PT, MILES BJ et al.: Sildenafil citrate after radical retropubic prostatectomy. J. Urol. (1999) 162:1614-1617.
14. WHO INTERNATIONAL SOCIETY FOR IMPOTENCE RESEARCH: Table 8-8: Table of sildenafil in clinical trials. Erectile Dysfunction, Health Publication Ltd (2000): 269.
15. ROSEN RC, CAPPELLERI JC, GENDRANO N: The International Index of Erectile Function (IIEF): a state-of-the-sciencereview. Int. J. Impot. Res. (2002) 14(4):226-244: